I still think Pfizer is in the loop on the hcv program.
Imagine another big pharma gets the deal and turn the drug into a blockduster one. That wouldn't look too good on Pfizer's ceo. He would have a lot of explaining to do to his board and shareholders. After all they did have positive results with the preclinical trials.